|
|
||||||||
The Annals of Thoracic Surgery, Vol 57, 999-1006, Copyright © 1994 by The Society of Thoracic Surgeons
EN Mendeloff, IY Liang, JA Swain and RE Clark
Using a thromboxane A2 receptor-specific antagonist, SQ 30,741, this study
was undertaken to define the role of thromboxane A2 in postischemic
myocardial reperfusion injury and in the heparin-protamine reaction.
Eighteen heparinized (300 units/kg) sheep were placed on cardiopulmonary
bypass (CPB) after complete instrumentation, cooled to 28 degrees C, and
had their aortas crossclamped for 1 hour. They were then rewarmed to 36
degrees C and weaned from CPB without inotropic support. Control sheep (n =
6) received a saline infusion throughout the procedure. Bolus animals (n =
6) received 5 mg/kg of SQ 30,741 at 5 minutes after discontinuation of CPB
and before protamine sulfate administration. Infusion animals (n = 6)
received an SQ 30,741 bolus of 5 mg/kg followed by a continuous infusion of
5 mg.kg-1 hr-1 of SQ 30,741 initiated before CPB. All animals received 5
mg/kg of protamine sulfate over a 15-second period 15 minutes after being
weaned from CPB. Control animals exhibited significantly decreased global
myocardial function after the 1-hour ischemic interval. Further significant
functional decline and increase in pulmonary pressure occurred after
protamine sulfate administration. Bolus animals experienced a similar
postischemic injury, but had no further decrease in function following
protamine infusion. Infusion animals had significantly improved global
myocardial function after bypass compared with both other groups and were
also protected from the deleterious effects of protamine sulfate
administration.(ABSTRACT TRUNCATED AT 250 WORDS)
ARTICLES
Thromboxane A2 receptor-specific antagonism in hypothermic cardiopulmonary bypass
Surgery Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD.
This article has been cited by other articles:
![]() |
R. Gerrah, A. Elami, A. Stamler, A. Smirnov, and Z. Stoeger Preoperative Aspirin Administration Improves Oxygenation in Patients Undergoing Coronary Artery Bypass Grafting Chest, May 1, 2005; 127(5): 1622 - 1626. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Hennein Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255. [Abstract] [PDF] |
||||
![]() |
L. J. Dacey, J. J. Munoz, E. R. Johnson, B. J. Leavitt, C. T. Maloney, J. R. Morton, E. M. Olmstead, J. D. Birkmeyer, and G. T. O'Connor Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients Ann. Thorac. Surg., December 1, 2000; 70(6): 1986 - 1990. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nakajima, K. Kawazoe, K. Ishibashi, Y. Kubota, T. Sasaki, H. Izumoto, and T. Nitatori Reduction of heparin dose is not beneficial to platelet function Ann. Thorac. Surg., July 1, 2000; 70(1): 186 - 190. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fehmi Katircioglu, T. Ulus, B. Yamak, Z. Saritas, and U. Yildiz Experimental Inhibition of Protamine Cardiotoxicity by Prostacyclin Angiology, November 1, 1999; 50(11): 929 - 935. [Abstract] [PDF] |
||||
![]() |
S. F. Katircioglu, D. S. Kucukaksu, O. Tasdemir, K. Bayazit, R. E. Clark, E. N. Mendeloff, I. Y.S. Liang, and J. A. Swain Arachidonic Acid Metabolism After Heparin Reversal With Protamine Ann. Thorac. Surg., February 1, 1995; 59(2): 550 - 551. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |